MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio.

Autor: Mestrum SGC; Department of Genetics & Cell Biology, GROW-Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Roanalis BYV; Department of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., de Wit NCJ; Central Diagnostic Laboratory (CDL), Maastricht University Medical Center, Maastricht, the Netherlands., Drent RJM; Department of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Boonen BT; Department of Orthopedic Surgery, Zuyderland Medical Center, Heerlen, the Netherlands., van Hemert WLW; Department of Orthopedic Surgery, Zuyderland Medical Center, Heerlen, the Netherlands., Hopman AHN; Department of Genetics & Cell Biology, GROW-Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Ramaekers FCS; Department of Genetics & Cell Biology, GROW-Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands; Nordic-MUbio, an Absolute Biotech Company, Susteren, the Netherlands., Leers MPG; Department of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands; Department of Environmental Sciences, Faculty of Science, Open Universiteit, Heerlen, the Netherlands. Electronic address: mat.leers@zuyderland.nl.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2024 Jul; Vol. 142, pp. 107520. Date of Electronic Publication: 2024 May 15.
DOI: 10.1016/j.leukres.2024.107520
Abstrakt: This study investigates the intertwined processes of (anti-)apoptosis and cell proliferation in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Utilizing antibodies to Bcl-2 and Ki-67, the CD34-positive blast cell compartments in bone marrow aspirates from 50 non-malignant cases, 25 MDS patients, and 25 AML patients were analyzed for their anti-apoptotic and proliferative cell fractions through ten-color flow cytometry. MDS patients exhibited a significantly increased anti-apoptotic (p=0.0014) and reduced proliferative cell fraction (p=0.0030) in their blast cell population as compared to non-malignant cases. AML patients showed an even more exacerbated trend than MDS patients. The resulting Bcl-2:Ki-67 cell fraction ratios in MDS and AML were significantly increased as compared to the non-malignant cases (p=0.0004 and p<0.0001, respectively). AML patients displayed, however, a high degree of variability in their anti-apoptotic and proliferation index, attributed to heterogeneity in maturation stage and severity of the disease at diagnosis. Using double-labeling for Bcl-2 and Ki-67 it could be shown that besides blast cells with a mutually exclusive Ki-67 and Bcl-2 expression, also blast cells concurrently exhibiting anti-apoptotic and proliferative marker expression were found. Integrating these two dynamic markers into MDS and AML diagnostic workups may enable informed conclusions about their biological behavior, facilitating individualized therapy decisions for patients.
Competing Interests: Declaration of Competing Interest F.C.S.R. is CSO and QA manager at Nordic-MUbio, Susteren, The Netherlands.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: